Gleiss Lutz advises founder on the sale of all shares in Roast Market to Melitta and Burda

​A Gleiss Lutz team has advised the co-founder and CEO of the coffee platform Roast Market on the sale of all shares to Melitta and Burda. In parallel, all other existing shareholders have sold their shares to Melitta and Burda. Melitta is a family-owned business that has held a minority shareholding in Roast Market for roughly the last two years. Together with the Burda subsidiary TEC, Melitta has now taken Roast Market over in full.

The parties have agreed not to disclose the purchase price. The transaction has already been cleared by the EU Commission, the competent antitrust authority, and executed.

Roast Market now offers more than 4100 products from more than 280 brands in the field of coffee, coffee machines and accessories. The company employs 122 staff at its registered office in Frankfurt and storage facility in Hanau, and is one of Germany's leading online distributors of coffee and accessories. Last year, Roast Market more than doubled its sales from 11 to 23 million euros.

A team led by Dr. Andreas Löhdefink has been assisting co-founder and CEO Dr. Boris Häfele and Roast Market since the company was founded.

The following Gleiss Lutz team advised Roast Market on the transaction: Dr Andreas Löhdefink (partner, lead, Frankfurt), Dr Rainer Loges (partner, Munich), Dr Christoph Auchter, Kevin Löffler (all M&A), Dr Thomas Winzer (partner), Dr Tobias Abend (counsel, both Employment), Dr Stefan Mayer (partner, all Frankfurt), Dr Alexander Werder (partner, Hamburg), Dr Ocka Stumm, Dr Dominik Monz, Dr Leonhard Kornwachs (all Tax, all Frankfurt), Dr Alexander Molle (partner, IP/IT, Berlin), Dr Kai Birke (partner), Dr Jan-Alexander Lange (both Finance, Frankfurt), Dr Andreas Spahlinger (partner), Dr Matthias Tresselt (partner, both Restructuring, Stuttgart), Josefine Chakrabarti (Employment, Berlin), Dr Wolfgang Bosch (partner, Competition/Antitrust), Dr Timo Bühler (counsel, Finance), Dr Felix Müller (IP/IT, Berlin), Dr Christopher Splinter (Corporate, Munich).